In the news release, Oncolytics Biotech® Inc. Announces Start of
Enrollment in Phase 1b Study of Multiple Myeloma Looking at
REOLYSIN® in Combination with Bortezomib, issued today by
Oncolytics Biotech Inc. over CNW, we are advised by the company
that the 1st paragraph, 1st sentence should have read "(VELCADE®)"
rather than "(Kyprolis®)" as originally issued inadvertently. The
complete, corrected release follows:
Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b
Study of Multiple Myeloma Looking at REOLYSIN® in Combination with
Bortezomib
CALGARY,
Nov. 18, 2015 /CNW/ - Oncolytics
Biotech Inc. ("Oncolytics") (TSX:ONC, OTCQX:ONCYF) today announced
that enrollment has commenced in a Phase Ib study of
REOLYSIN® combined with standard doses of bortezomib
(VELCADE®) and dexamethasone in patients with relapsed
or refractory multiple myeloma (REO 019). Kevin Kelly, M.D., Ph.D. of the Keck School of
Medicine of the University of Southern
California (USC), is the
principal investigator.
"We recently announced promising early results
from another multiple myeloma study examining REOLYSIN®
in combination with carfilzomib," said Dr. Brad Thompson, President and CEO of Oncolytics.
"Our goal is to determine how REOLYSIN® performs with
the standard of care options in this difficult to treat indication
and then take the best combination forward into later-stage
testing."
The study is a two-stage open-label Phase Ib
trial of adult patients with relapsed or refractory multiple
myeloma following at least one line of therapy. The study
objectives include determining the maximum tolerated dose ("MTD")
and the safety profile of REOLYSIN® in combination with
bortezomib and dexamethasone, as well as exploring the toxicities
and the pharmacodynamics of the treatment combination, and
determining the preliminary response rate in patients with relapsed
or refractory multiple myeloma.
Adult patients will receive REOLYSIN®
on days 1, 2, 8, 9, 15 and 16 of each 28-day cycle. Patients will
also receive bortezomib and dexamethasone on days 1, 8 and 15.The
first stage of the study will enroll three to six patients in each
of two cohorts, with each cohort at a different dose level. The
second stage of the study will enroll up to 12 patients at the MTD
reached in the first stage.
About Multiple Myeloma
Multiple Myeloma
is a cancer of the plasma cells and the second most common
hematological malignancy. The American Cancer Society estimates
there will be 26,850 new cases diagnosed in the United States and 11,240 deaths from the
disease in 2015.
About Oncolytics Biotech
Inc.
Oncolytics is a Calgary-based biotechnology company focused on
the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics' clinical program includes a variety
of later-stage, randomized human trials in various indications
using REOLYSIN®, its proprietary formulation of the
human reovirus. For further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933,
as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian
securities laws. Statements, other than statements of historical
facts, included in this press release that address activities,
events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as, the Company's
expectations related to the phase 1b
study in relapsed or refractory multiple myeloma, future trials in
this indication, the Company's belief as to the potential of
REOLYSIN® as a cancer therapeutic, and other such
matters are forward-looking statements and forward-looking
information and involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially
from those in the forward-looking statements and forward-looking
information. Such risks and uncertainties include, among others,
risks related to the statistical sufficiency of patient enrollment
numbers in separate patient groups, the availability of funds and
resources to pursue research and development projects, the efficacy
of REOLYSIN® as a cancer treatment, the tolerability of
REOLYSIN® outside a controlled test, the success and
timely completion of clinical studies and trials, the Company's
ability to successfully commercialize REOLYSIN®,
uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements and forward-looking information.
Investors are cautioned against placing undue reliance on
forward-looking statements and forward-looking information. The
Company does not undertake to update these forward-looking
statements and forward-looking information, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.
